FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159215031> ?p ?o ?g. }

• W3159215031 endingPage "1713" @default.
• W3159215031 startingPage "1706" @default.
• W3159215031 abstract "Silent corticotroph adenomas (SCAs) are a distinct subtype of nonfunctioning pituitary adenomas (NFAs) that demonstrate positive immunohistochemistry for adrenocorticotropic hormone (ACTH) without causing Cushing's disease. SCAs are hypothesized to exhibit more aggressive behavior than standard NFAs. The authors analyzed their institution's surgical experience with SCAs in an effort to characterize rates of invasion, postoperative clinical outcomes, and patterns of disease recurrence and progression. The secondary objectives were to define the best treatment strategies in the event of tumor recurrence and progression.A retrospective analysis of patients treated at the authors' institution identified 100 patients with SCAs and 841 patients with NFAs of other subtypes who were treated surgically from 2000 to 2019. Patient demographics, tumor characteristics, surgical and neuroimaging data, rates of endocrinopathy, and neurological outcomes were recorded. Cohorts of patients with SCAs and patients with standard NFAs were compared with regard to these characteristics and outcomes.The SCA cohort presented with cranial neuropathy (13% vs 5.7%, p = 0.0051) and headache (53% vs 42.3%, p = 0.042) compared to the NFA cohort, despite similar rates of apoplexy. The SCA cohort included a higher proportion of women (SCA 60% vs NFA 45.8%, p = 0.0071) and younger age at presentation (SCA 50.5 ± 13.3 vs NFA 54.6 ± 14.9 years of age, p = 0.0082). Reoperations were comparable between the cohorts (SCA 16% vs NFA 15.7%, p = 0.98). Preoperative pituitary function was comparable between the cohorts with the exception of higher rates of preoperative panhypopituitarism in NFA patients (2% vs 6.1%, respectively; p = 0.0033). The mean tumor diameter in SCA patients was 24 ± 10.8 mm compared to 26 ± 11.3 mm in NFA patients (p = 0.05). Rates of cavernous sinus invasion were higher in the SCA group (56% vs 49.7%), although this result did not reach statistical significance. There were no significant differences in extent of resection, intraoperative CSF leak rates, endocrine or neurological outcomes, or postoperative complications. Ki-67 rates were significantly increased in the SCA cohort (2.88 ± 2.79) compared to the NFA cohort (1.94 ± 1.99) (p = 0.015). Although no differences in overall rates of progression or recurrence were noted, SCAs had a significantly lower progression-free survival (24.5 vs 51.1 months, p = 0.0011). Among the SCA cohort, progression was noted despite the use of adjuvant radiosurgery in 33% (n = 4/12) of treated tumors. Adequate tumor control was not achieved in half (n = 6) of the SCA progression cohort despite radiosurgery or multiple resections.In this study, to the authors' knowledge the largest surgical series to assess outcomes in SCAs to date, the findings suggest that SCAs are more biologically aggressive tumors than standard NFAs. The progression-free survival duration of patients with SCAs is only about half that of patients with other NFAs. Therefore, close neuroimaging and clinical follow-up are warranted in patients with SCAs, and residual disease should be considered for early postoperative adjuvant radiosurgery, particularly in younger patients." @default.
• W3159215031 created "2021-05-10" @default.
• W3159215031 creator A5001850673 @default.
• W3159215031 creator A5009768431 @default.
• W3159215031 creator A5014501231 @default.
• W3159215031 creator A5041804386 @default.
• W3159215031 creator A5048709528 @default.
• W3159215031 creator A5060200001 @default.
• W3159215031 creator A5060324899 @default.
• W3159215031 creator A5061263498 @default.
• W3159215031 creator A5074414013 @default.
• W3159215031 creator A5085362780 @default.
• W3159215031 creator A5091278469 @default.
• W3159215031 date "2021-12-01" @default.
• W3159215031 modified "2023-10-16" @default.
• W3159215031 title "Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence" @default.
• W3159215031 cites W1901079694 @default.
• W3159215031 cites W1919216911 @default.
• W3159215031 cites W1981171396 @default.
• W3159215031 cites W1982756072 @default.
• W3159215031 cites W2011096934 @default.
• W3159215031 cites W2015684872 @default.
• W3159215031 cites W2016970675 @default.
• W3159215031 cites W2030604268 @default.
• W3159215031 cites W2033680813 @default.
• W3159215031 cites W2036610131 @default.
• W3159215031 cites W2039899387 @default.
• W3159215031 cites W2052640332 @default.
• W3159215031 cites W2062019831 @default.
• W3159215031 cites W2088975177 @default.
• W3159215031 cites W2123761756 @default.
• W3159215031 cites W2611297552 @default.
• W3159215031 cites W2761810592 @default.
• W3159215031 cites W2779137890 @default.
• W3159215031 cites W2906826594 @default.
• W3159215031 cites W3006874692 @default.
• W3159215031 cites W3016602435 @default.
• W3159215031 cites W4242844295 @default.
• W3159215031 doi "https://doi.org/10.3171/2020.10.jns203236" @default.
• W3159215031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33962375" @default.
• W3159215031 hasPublicationYear "2021" @default.
• W3159215031 type Work @default.
• W3159215031 sameAs 3159215031 @default.
• W3159215031 citedByCount "8" @default.
• W3159215031 countsByYear W31592150312021 @default.
• W3159215031 countsByYear W31592150312022 @default.
• W3159215031 countsByYear W31592150312023 @default.
• W3159215031 crossrefType "journal-article" @default.
• W3159215031 hasAuthorship W3159215031A5001850673 @default.
• W3159215031 hasAuthorship W3159215031A5009768431 @default.
• W3159215031 hasAuthorship W3159215031A5014501231 @default.
• W3159215031 hasAuthorship W3159215031A5041804386 @default.
• W3159215031 hasAuthorship W3159215031A5048709528 @default.
• W3159215031 hasAuthorship W3159215031A5060200001 @default.
• W3159215031 hasAuthorship W3159215031A5060324899 @default.
• W3159215031 hasAuthorship W3159215031A5061263498 @default.
• W3159215031 hasAuthorship W3159215031A5074414013 @default.
• W3159215031 hasAuthorship W3159215031A5085362780 @default.
• W3159215031 hasAuthorship W3159215031A5091278469 @default.
• W3159215031 hasConcept C126322002 @default.
• W3159215031 hasConcept C143998085 @default.
• W3159215031 hasConcept C167135981 @default.
• W3159215031 hasConcept C2776810848 @default.
• W3159215031 hasConcept C2777428134 @default.
• W3159215031 hasConcept C2777658017 @default.
• W3159215031 hasConcept C2779134260 @default.
• W3159215031 hasConcept C2779318953 @default.
• W3159215031 hasConcept C2780546910 @default.
• W3159215031 hasConcept C71315377 @default.
• W3159215031 hasConcept C71924100 @default.
• W3159215031 hasConcept C72563966 @default.
• W3159215031 hasConcept C79381400 @default.
• W3159215031 hasConcept C90924648 @default.
• W3159215031 hasConceptScore W3159215031C126322002 @default.
• W3159215031 hasConceptScore W3159215031C143998085 @default.
• W3159215031 hasConceptScore W3159215031C167135981 @default.
• W3159215031 hasConceptScore W3159215031C2776810848 @default.
• W3159215031 hasConceptScore W3159215031C2777428134 @default.
• W3159215031 hasConceptScore W3159215031C2777658017 @default.
• W3159215031 hasConceptScore W3159215031C2779134260 @default.
• W3159215031 hasConceptScore W3159215031C2779318953 @default.
• W3159215031 hasConceptScore W3159215031C2780546910 @default.
• W3159215031 hasConceptScore W3159215031C71315377 @default.
• W3159215031 hasConceptScore W3159215031C71924100 @default.
• W3159215031 hasConceptScore W3159215031C72563966 @default.
• W3159215031 hasConceptScore W3159215031C79381400 @default.
• W3159215031 hasConceptScore W3159215031C90924648 @default.
• W3159215031 hasIssue "6" @default.
• W3159215031 hasLocation W31592150311 @default.
• W3159215031 hasLocation W31592150312 @default.
• W3159215031 hasOpenAccess W3159215031 @default.
• W3159215031 hasPrimaryLocation W31592150311 @default.
• W3159215031 hasRelatedWork W1965912648 @default.
• W3159215031 hasRelatedWork W1969557795 @default.
• W3159215031 hasRelatedWork W1993860678 @default.
• W3159215031 hasRelatedWork W2016115159 @default.
• W3159215031 hasRelatedWork W2022069463 @default.
• W3159215031 hasRelatedWork W2027650565 @default.

• next